Skip to main content

Advertisement

SpringerLink
Log in

Current and emerging treatment approaches for tobacco dependence

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Nicotine in tobacco is the primary reason why most people find it hard to stop using tobacco. Nicotine creates dependence by activating the dopaminergic reward system in the brain. Physiologic withdrawal symptoms that occur when nicotine is no longer administered reinforce continued nicotine administration to avoid withdrawal. Extrapolating from this evidence has led to the development of tobacco dependence pharmacotherapy based upon the concept of replacing and/or blocking the effects of nicotine in the brain. The efficacy of nicotine replacement and blockade treatments in lessening symptoms of nicotine withdrawal and increasing quit rates has been consistently demonstrated in clinical trials. Despite the availability of efficacious medications to treat nicotine dependence, current therapies remain underutilized across the population. Health-care providers need to systematically encourage all tobacco users to quit and ensure that their tobacco-using patients use evidence-based treatments when they attempt to quit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Centers for Disease Control and Prevention. Cigarette smoking among adults—United States, 2004. Morbid Mortal Wk Rep MMWR 2005, 54:1121–1124. This paper provides recent data on the prevalence of smoking among adults in the United States.

  2. Edwards BK, Brown BL, Wingo PA, et al.: Annual report to the nation on the status of cancer, 1975—2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005, 97:1407–1427.

    Article  PubMed  Google Scholar 

  3. Euromonitor International 2006. The World Market for Tobacco. http://www.euromonitor.com. Accessed 8/28/06.

  4. Hyland A, Li Q, Bauer J, et al.: Predictors of cessation in a cohort of current and former smokers followed over 13 years. Nicotine Tob Res, 2004, 6(Suppl III):S363-S369.

    Article  PubMed  Google Scholar 

  5. Hyland A, Borland R, Li Q, et al.: Core predictors for quitting from the international tobacco control policy evaluation study. Tob Control 2006, 15(Suppl III):iii83-iii94.

    Article  PubMed  Google Scholar 

  6. Centers for Disease Control and Prevention: Cigarette smoking among adults—United States, 2000. Morbid Mortal Wk Rep MMWR 2002, 51:642–645.

  7. Doll R, Peto R, Boreham J, Sutherland I: Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 2004, 328:1519–1528. This article provides 50-year follow-up data on a study of 34,439 male British doctors that began in 1951. By 2001, most of the participants had died, so this paper provides a fairly comprehensive assessment of the mortality attributable to cigarette smoking and benefits of smoking cessation.

    Article  PubMed  Google Scholar 

  8. Cummings KM, Giovino DA: Selling the “quit” brand to young adult smokers. J Gen Intern Med 2004, 19:481–482.

    Article  PubMed  Google Scholar 

  9. Fielding JE, Briss PA, Carande-Kulis VG, et al.: Tobacco. In The Guide to Community Preventive Services. Edited by Zaza S, Briss PA, Harris KW. New York, NY: Oxford University Press; 2005:1–79. Also accessible at http://www. thecommunityguide.org/tobacco. Accessed 8/31/06. This chapter provides concise summaries of the evidence supporting the effectiveness of population-based interventions for tobacco prevention, cessation, and control.

    Google Scholar 

  10. Fiore M, Croyle R, Curry S. et al.: Preventing 3 million premature deaths and helping 5 million smokers quit: A national action plan for tobacco cessation. Am J Pub Health 2004, 94:205–210. This article summarizes the recommendations of a blue-ribbon panel of experts appointed by the US Department of Health and Human Services to examine ways to increase rates of smoking cessation.

    PubMed  Google Scholar 

  11. Biener L, Reimer RL, Wakefield M, et al.: Impact of smoking cessation aids among recent quitters. Am J Prev Med 2006, 30:217–224. This article demonstrates that mass media campaigns that reach large segments of the population have a bigger overall impact on promoting smoking cessation than do most other cessation interventions.

    Article  PubMed  Google Scholar 

  12. Frieden TR, Mostashari F, Kerker BD, et al.: Adult tobacco use levels after intensive tobacco control measures: New York City, 2002–2003. Am J Public Health 2005, 95:1016–1023. This article shows how combining policy and population-based program interventions has worked to accelerate a decline in adult tobacco use in New York City.

    Article  PubMed  Google Scholar 

  13. The Health Consequences of Smoking: Nicotine Addiction. A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services Centers for Disease Control, Office on Smoking or Health; 1988.

  14. Hurt RD, Robertson CR: Prying open the door to the cigarette industry’s secrets about nicotine—the Minnesota Tobacco Trial. JAMA 1998, 280:1173–1181.

    Article  PubMed  CAS  Google Scholar 

  15. Dunn WL Jr.: Motives and Incentives in Cigarettes. Richmond, VA: Philip Morris Research Center; 1972.

    Google Scholar 

  16. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA: Nicotine activates and desensitizes midbrain dopamine neurons. Nature 1997, 390:401–404.

    Article  PubMed  CAS  Google Scholar 

  17. Fiore MC, Novotny TE, Pierce JP, et al.: Methods used to quit smoking in the United States. Do cessation programs help? JAMA 1990, 263:2760–2765.

    Article  PubMed  CAS  Google Scholar 

  18. Fiore MC, Bailey WC, Cohen SJ, et al.: Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, 2000.

    Google Scholar 

  19. Cummings KM, Hyland A: Impact of nicotine replacement therapy on smoking behavior. Annu Rev Public Health 2005, 26:583–599.

    Article  PubMed  Google Scholar 

  20. Silagy C, Lancaster T, Stead L, Mant D, Fowler G: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2002, 4:CD000146.

    PubMed  Google Scholar 

  21. Shiffman S, Fant RV, Gitchell JG: Nicotine delivery systems: How far has technology come? Am J Drug Deliv 2003, 1:112–124.

    Google Scholar 

  22. Blondal T, Gudmundsson LJ, Olafsdottir I, et al.: Nicotine nasal spray with nicotine patch for smoking cessation: Randomized trial with six year follow up. BMJ 1999, 318:285–288.

    PubMed  CAS  Google Scholar 

  23. Kornitzer M, Boutsen M, Dramaix M, et al.: Combined use of nicotine patch and gum in smoking cessation: a placebocontrolled clinical trial. Prev Med 1995, 24:41–47.

    Article  PubMed  CAS  Google Scholar 

  24. Puska P, Korhonen H, Vartiainen E, et al.: Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. Tob Control 1995, 4:231–235.

    Article  Google Scholar 

  25. Benowitz NL. Nicotine Safety and Toxicity. New York: Oxford Univ. Press; 1998.

    Google Scholar 

  26. Kimmel SE, Berlin JA, Miles C, et al.: Risk of acute first myocardial infarction and use of nicotine patches in a general population. J Am Coll Cardiol 2001, 37:1297–1302.

    Article  PubMed  CAS  Google Scholar 

  27. Park CR, Munday DL: Development and evaluation of a biphasic buccal adhesive tablet for nicotine replacement therapy. Int J Pharmacol 2002, 237:215–226.

    Article  CAS  Google Scholar 

  28. Freedman AM: Philip Morris memo likens nicotine to drugs. Wall Street Journal; December 8, 1995.

  29. Kozlowski LT, Strasser AA, Giovino GA, et al.: Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction. Tob Control 2001, 10:201–203.

    Article  PubMed  CAS  Google Scholar 

  30. Foulds J, Ramstrom L, Burke M, Fagerstrom K: Effect of smokeless tobacco [snus] on smoking and public health in Sweden. Tob Control 2003, 12:349–359.

    Article  PubMed  CAS  Google Scholar 

  31. Seller EM, Kaplan HL, Tyndale RF: Inhibition of cytochrome P450 2A6 increases nicotine’s oral bioavailability and decreases smoking. Clin Pharmacol Ther 2000, 68:35–43.

    Article  Google Scholar 

  32. Dale LC, Hurt RD, Offord KP et al.: High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA 1995, 274:1353–1358.

    Article  PubMed  CAS  Google Scholar 

  33. George TO, O’Malley SS: Current pharmacological treatments for nicotine dependence. Trends Pharmcol Sci 2004, 25:42–48.

    Article  CAS  Google Scholar 

  34. Johnstone EC, Yudkin PL, Hey K, et al.: Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004, 14:8390.

    Article  Google Scholar 

  35. Warner C, Shoaib M: How does bupropion work as a smoking cessation aid? Addict Biol 2005, 10:219–231.

    Article  PubMed  CAS  Google Scholar 

  36. Richmond R, Zwar N: Review of bupropion for smoking cessation. Drug Alcohol Rev 2003, 22:203–220.

    Article  PubMed  Google Scholar 

  37. Wagena EJ, Knipschild P, Zeegers MP: Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction 2005, 100:317–26.

    Article  PubMed  CAS  Google Scholar 

  38. Foulds J: The neurobiolgical basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract 2006, 60:571–576. This article summarizes the recent data available on varenicline, which was just approved by the FDA for the treatment of tobacco dependence.

    Article  PubMed  CAS  Google Scholar 

  39. Cohen C, Bergis OE, Galli F, et al.: SSR591813, a novel selective and partial ? 4?2 nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther 2003, 306:407–420.

    Article  PubMed  CAS  Google Scholar 

  40. Despres JP, Golay A, Sjostrom, for the Rimonabant in Obesity-Lipids Study Group: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121–2134.

    Article  PubMed  CAS  Google Scholar 

  41. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al.: for the Rimonabant in Obesity-North America Study Group: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761–775.

    Article  PubMed  CAS  Google Scholar 

  42. Hieda Y, Keyler DE, VanDeVoort JT, et al.: Immunization of rats reduces nicotine distribution to brain. Psychopharmacology 1999, 143:150–157.

    Article  PubMed  CAS  Google Scholar 

  43. Hatsukami DK, Rennard S, Jorenby D et al.: Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 2005, 78:456–467. This article provides the first published human data on the nicotine vaccine. The results show that the vaccine was well tolerated by subjects and stimulated antibodies in the majority of subjects.

    Article  PubMed  CAS  Google Scholar 

  44. Rose JE, Behm FM: There is more to smoking than the CNS effects of nicotine. In Effects of Nicotine on Biological Systems II. Edited by Clark PBS. Basel: Burkhaser Verlag, 1995:9–16.

    Google Scholar 

  45. Brauer LH, Behm FM, Lane JD, et al.: Individual differences in smoking reward from de-nicotinized cigarettes. Nicotine Tob Res 2001, 3:101–109.

    Article  PubMed  CAS  Google Scholar 

  46. Butschky MF, Bailey D, Henningfield JE, Pickworth WB: Smoking without nicotine delivery decreases withdrawal in 12-hour abstinence smokers. Pharmacol Biochem Behav 1995, 50:91–96.

    Article  PubMed  CAS  Google Scholar 

  47. Rose JE, Levin ED: Inter-relationships between conditioned and primary reinforcement in the maintenance of cigarette smoking. Br J Addict 1991, 86:606–609.

    Article  Google Scholar 

  48. Rose JE, Behm FM, Westman EC, Kukovich P: Precessation treatment with nicotine skin patch facilities smoking cessation. Nicotine Tob Res 2006, 8:89–101.

    Article  PubMed  CAS  Google Scholar 

  49. Lancaster T, Stead L: Physician advice for smoking cessation. Cochrane Database Syst Rev 2004, 4:CD000165. This articles provides a meta-analysis of the effects of health provider advice to stop smoking. The results demonstrate that even brief counseling by a health-care provider can stimulate cessation attempts and increase quit rates.

    PubMed  Google Scholar 

  50. Cokkinides VE, Ward E, Jemal A, Thun J: Under-use of smoking cessation treatments. Am J Prev Med 2005, 28:119–122.

    Article  PubMed  Google Scholar 

  51. Bansal M, Cummings KM, Hyland A, Giovino GA: Stop smoking medications: Who uses them, who misuses them, and who is misinformed about them. Nicotine Tob Res 2004, 6(Suppl 3):S303-S310.

    Article  PubMed  Google Scholar 

  52. Theobold M, Jaen CR: An update on tobacco cessation reimbursement: slowly but surely, it’s getting easier to help your patients kick the habit. Fam Practice Manage 2006, 13:75–78.

    Google Scholar 

  53. McPhillips-Tangum C, Bocchino C, Carreon R, et al.: Addressing tobacco in managed care: results of the 2002 survey. Prev Chronic Dis 2004, 1:18–24.

    Google Scholar 

  54. Schroeder SA: What to do with a patient who smokes. JAMA 2005, 294:482–487. This article provides practical suggestions for health-care providers to use with their patients who smoke.

    Article  PubMed  CAS  Google Scholar 

  55. Etter JF, Perneger TV: Attitudes toward nicotine replacement therapy in smokers and ex-smokers in the general public. Clin Pharmacol Ther 2001, 69:175–183.

    Article  PubMed  CAS  Google Scholar 

  56. Cummings KM, Fix B, Celestino P, et al.: Reach, efficacy, and cost-effectiveness of free nicotine medication giveaway programs. J Public Health Manage Pract 2006, 12:37–43.

    Google Scholar 

  57. Miller N, Frieden TR, Liu SY, et al.: Effectiveness of a large-scale distribution programme of free nicotine patches: a prospective evaluation. Lancet 2005, 365:1849–1854.

    Article  PubMed  Google Scholar 

  58. Cummings KM, Hyland A, Fix B, et al.: Free nicotine patch giveaway program 12-month follow-up of participants Am J Prev Med 2006, 31:181–184.

    Article  PubMed  Google Scholar 

  59. Willemsen MC, Simons C, Zeeman G: Impact of the new EU health warnings on the Dutch quit line. Tob Control 2002, 11:381–382.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Health Behavior, Roswell Park Cancer Institute, Elm and Carlton Streets, 14263, Buffalo, NY, USA

    K. Michael Cummings PhD, MPH

Authors
  1. K. Michael Cummings PhD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Mahoney MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Michael Cummings PhD, MPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cummings, K.M., Mahoney, M. Current and emerging treatment approaches for tobacco dependence. Curr Oncol Rep 8, 475–483 (2006). https://doi.org/10.1007/s11912-006-0077-6

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-006-0077-6

Keywords

Search

Navigation